Special Issue "Neutralizing-Antibody-Based Treatments for COVID-19: Achievements and Lessons Learnt for Future Pandemics"
Deadline for manuscript submissions: closed (28 February 2022) | Viewed by 17911
Interests: virology; emerging viruses; pandemics; viral evolution; hematology; immunogenetics; transplant immunology; transfusion medicine
Special Issues, Collections and Topics in MDPI journals
Special Issue in International Journal of Molecular Sciences: SARS-CoV-2 Variants, Antibodies and Vaccines
Special Issue in Life: COVID-19 Convalescent Plasma for Immuno-Compromised Patients
Special Issue in Viruses: Emerging Concepts in SARS-CoV-2 Biology and Pathology
Special Issue in Life: Epidemiology of Viral Zoonosis
Special Issue in Viruses: Emerging Concepts in SARS-CoV-2 Biology and Pathology 2.0
Special Issue in International Journal of Molecular Sciences: Influenza Viruses: Infection and Genomics
The ongoing COVID-19 pandemic has caused more than 2 million deaths worldwide, which are still counting. Small-chemical antivirals and immunosuppressive treatments are not always efficacious, but passive and active immunotherapies based on neutralizing antibodies show potential. Convalescent COVID-19 plasma is a pioneer in the field, with monoclonal antibodies now entering the market and hyperimmune serum on the horizon. The vaccines approved to date are based on the induction of anti-Spike antibodies. The emergence of Spike variants is affecting the entire field, so challenges will remain for the coming months. In this Special Issue, we will summarize the achievements to date for all treatments based on neutralizing antibodies against COVID-19, and lessons that could prevent errors in future pandemics.
Dr. Daniele Focosi
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Life is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- convalescent plasma
- COVID-19 convalescent plasma (CCP)
- hyperimmune serum
- polyclonal immunoglobulins